Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.95 |
| ▸ | CA2 | P00918 | 4/20 | 0.95 |
| ▸ | CA12 | O43570 | 3/20 | 0.95 |
| ▸ | CA7 | P43166 | 3/20 | 0.95 |
| ▸ | CA9 | Q16790 | 3/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.95 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL3690 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL30233582 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL2053863 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29349919 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8922036 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL450480 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10975219 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10978035 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3981503 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10980548 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012114342-A1 | FLUMAZENIL COMPLEXES, COMPOSITIONS COMPRISING SAME AND USES THEREOF | COERULEUS LTD. (IL) | 2012-08-30 | — | — | WO | claimed |
| CN-116410727-A | Dilution thickening type surfactant spherical micelle super-concentrated dispersion system, and preparation method and application thereof | 武汉大学 | 2023-07-11 | — | — | CN | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | disclosed |
| US-9592216-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | ACTION MEDICINES, S.L. (ES) | 2017-03-09 | — | — | US | disclosed |
| US-9585893-B2 | Flumazenil complexes, compositions comprising same and uses thereof | COERULEUS LTD. (IL) | 2017-03-07 | — | — | US | disclosed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020027-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| US-4497744-A | Gentisic acid salts as radiographic scanning agent stabilizers | MALLINCKRODT, INC. (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0004684-B1 | STABILIZED RADIOGRAPHIC SCANNING AGENTS AND METHOD FOR PREPARING THEM | THE PROCTER & GAMBLE COMPANY (US) | 1981-09-16 | — | — | EP | disclosed |
| US-4233284-A | GENESTIC ACID, SALT OR ESTER THEREOF IN COMBINATION WITH A PERTECHNETATE REDUCING AGENT BECOMES LOCALIZED IN SPECIFIC BODY ORGANS OR BONES | THE PROCTER & GAMBLE COMPANY (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0004684-A2 | Stabilized radiographic scanning agents and method for preparing them | THE PROCTER & GAMBLE COMPANY (US) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | CA1 2993/4885CA2 899/4885CA12 1207/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | CA1 1782/4885CA2 463/4885CA12 431/4885 |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | CA1 1782/4885CA2 463/4885CA12 431/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | CA1 1782/4885CA2 463/4885CA12 431/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | CA1 2993/4885CA2 899/4885CA12 1207/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | CA1 312/4885CA2 340/4885CA12 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.